2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

If there is a single sentence that captures the modern science of cholesterol, it is the one this guideline put at its center: lower is better, for longer is better still. The 2019 ESC/EAS dyslipidaemia guidelines are the most aggressive — and arguably the most evidence-faithful — lipid recommendations issued by a major body.

Where the American guidelines hedged on numerical targets, this document committed. For very high-risk patients it set an LDL goal below 55 mg/dL and at least a 50 percent reduction from baseline; for high-risk patients, below 70. It folded PCSK9 inhibitors formally into the treatment ladder — high-intensity statin, then ezetimibe, then a PCSK9 inhibitor — and incorporated apolipoprotein B and non-HDL cholesterol as secondary targets. It also recommended measuring lipoprotein(a) at least once in every adult’s lifetime.

These targets were not chosen casually. They rest on the FOURIER and ODYSSEY OUTCOMES trials, the Cholesterol Treatment Trialists’ meta-analyses, and Mendelian randomization data — the convergent evidence that the relationship between LDL and cardiovascular events is causal, cumulative, and continuous well below the levels older guidelines treated as adequate.

The fair criticisms are practical. The targets are demanding and, for some patients, require expensive drugs; the guideline is calibrated to European practice and gives limited attention to cost-effectiveness; and where randomized data ran out, expert consensus filled the gap.

We rate the evidence very strong. Rigorous, comprehensive, and built on the best available causal evidence, it is the document that most clearly translated “lower LDL, earlier” from trial result into clinical instruction.